
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Category Reports Biotech
Tickers reports and analysis
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Larimar $LRMR Stock: FDA Path vs $UNCY $MBRX $HELP

Larimar has completed its rolling BLA, Unicycive has a March 25, 2027 FDA date, Moleculin needs a dose and Helus needs a second pivotal win. Four November 16 updates, four different hurdles, and the cash each company has to clear them.
Ligand $LGND $RPRX $HALO $IONS: Drug Royalties

Four drug royalty models compared: purchased rights, delivery technology, partnerships, contract duration, accounting and the cash shareholders retain.
Revolution $RVMD $VSTM $ERAS $LLY: RAS Strategies

Compare RAS and KRAS cancer programs: mutation selectivity, trial populations, safety, combinations and the different financial exposure of four companies.
BioCryst $BCRX $IONS $TAK $NTLA: HAE Treatment Choices

BioCryst, Ionis, Takeda and Intellia compare across HAE prevention, gene editing, patient choice, clinical evidence and business economics.
Praxis $PRAX $RAPP $STOK $XENE: Beyond Seizure Counts

Praxis, Rapport, Stoke and Xenon approach epilepsy through different mechanisms, clinical endpoints, regulatory paths and treatment models.
Biotech Radar — October 30, 2026: $ABOS, $AGIO, $NRXP, $REGN

Acumen, Agios, NRx and Regeneron lead the October 30 biotech Radar: clinical data, FDA decisions, earnings, deals and the catalyst calendar.
Biotech Radar — October 26–27, 2026: $ARTV, $BEAM, $MRK, $PFE

Artiva, Beam, Merck and Pfizer lead the October 26–27 Biotech Radar, covering clinical trials, FDA news, deals, earnings and upcoming events.
Who Pays for the Launch? $OTLK $IOVA $IBRX $VRNA

How Outlook, Iovance, ImmunityBio and Verona funded life after approval: launch costs, reimbursement, cash flow and shareholder economics.
The Cost of a Setback: Four Biotechs, Four Futures to Reprice — $EYPT, $OMER, $VNDA, $BNTX

Four biotech setbacks, four different costs: EyePoint, Omeros, Vanda and BioNTech compared through clinical evidence, cash, timing and dilution.
Biotech Radar — October 20, 2026: $RAPP, $AMGN, $RCUS, $TEVA

Rapport, Amgen, Arcus and Teva lead the Biotech Radar, with clinical results, regulatory news, deals and upcoming catalysts across the sector.
HCM Catalysts: $EWTX vs $CYTK $BMY $TNYA

EDG-7500 versus aficamten, mavacamten and TN-201: HCM subgroups, pivotal-study plans, ownership changes and biotech catalyst risks.
Vaccine Catalysts: $PCVX vs $MRK $PFE $SNY

Vaxcyte versus Merck, Pfizer and Sanofi after OPUS-1: adult and pediatric markets, immunogenicity limits, financing and next catalysts.
FcRn Catalysts: $IMVT vs $ARGX $JNJ $UCBJY

Immunovant and three FcRn competitors: gMG, Graves disease, the CLE setback, upcoming milestones and the correct UCB OTC ticker.
Ovarian Cancer: $ZNTL vs $ABBV $CORT $RHHBY

Azenosertib versus three ovarian-cancer benchmarks: ESMO disclosures, the 2027 DENALI window, biomarker overlap and regulatory risk.
Hyperinsulinism: $RZLT $AMLX ZEAL(CPH) 128940(KOSPI)

Rezolute versus Amylyx, Zealand and Hanmi: separate congenital and tumor hyperinsulinism, regulatory uncertainty and catalyst timing.
PRMT5 Catalysts: $TNGX vs $BMY $IDYA $AZN

Tango and three PRMT5 rivals compared: the ESMO window, MTAP selection, combination evidence and the risks behind a biotech run-up.
Duchenne: who remains outside the options at $CAPR, $SRPT, $RGNX and $DYN?

Compare Capricor, Sarepta, REGENXBIO and Dyne by mutation, age, walking ability, safety and the difference between trial access and approval.
Sickle cell: what progress means for $AGIO, $CRSP, $BEAM and $NVO

Compare Agios, CRISPR, Beam and Novo Nordisk through hemoglobin, painful crises, transfusions and durable outcomes in sickle cell disease.
MASH beyond weight loss: what $ALT, $VKTX, $IVA and $MDGL actually have to prove

Compare Altimmune, Viking, Inventiva and Madrigal through liver fat, MASH resolution, fibrosis and the evidence still needed beyond weight loss.
Biotech Radar, October 7: regulatory progress, Parkinson’s data and oncology milestones

Five biotech updates, five different kinds of progress: regulatory review, exploratory Parkinson’s data, a Canadian approval and oncology enrollment milestones.



